PT  - JOURNAL ARTICLE
AU  - Yamana, Teresa
AU  - Pei, Sen
AU  - Kandula, Sasikiran
AU  - Shaman, Jeffrey
TI  - Projection of COVID-19 Cases and Deaths in the US as Individual States Re-open May 4, 2020
AID  - 10.1101/2020.05.04.20090670
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.04.20090670
4099  - http://medrxiv.org/content/early/2020/05/13/2020.05.04.20090670.short
4100  - http://medrxiv.org/content/early/2020/05/13/2020.05.04.20090670.full
AB  - In March and April 2020, control measures enforcing social distancing and restricting individual movement and contact were adopted across the United States in an effort to slow the spread and growth of COVID-19. However, a number of states have now begun to ease these restrictions. Here, we evaluate the effects of loosening stay-at-home orders on COVID-19 incidence and related outcomes. We use a metapopulation model applied at county resolution to simulate the spread and growth of COVID-19 incidence in the United States. We calibrate the model against county-level daily case and death data collected from February 21, 2020 to May 2, 2020, and project the outbreak in 3,142 US counties for 6 weeks into the future. Projections for daily reported cases, daily new infections (both reported and unreported), new and cumulative hospital bed demand, ICU bed and ventilator demand, as well as daily mortality, are generated. We observe a rebound in COVID-19 incidence and deaths beginning in late May, approximately 2 to 4 weeks after states begin to reopen. Importantly, the lag between infection acquisition and case confirmation, coupled with insufficient broader testing and contact tracing, will mask any rebound and exponential growth of the COVID-19 until it is well underway.Competing Interest StatementJS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.Funding StatementThis work was supported by US NIH grant GM110748 and US NSF RAPID grant DMS2027369.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll input data are publicly available; the model output is available at https://github.com/shaman-lab/COVID-19Projection